168 related articles for article (PubMed ID: 38514488)
1. Identification roles of NFE2L3 in digestive system cancers.
Li F; Wen Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):150. PubMed ID: 38514488
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of NFE2L3 promotes the development of gastric cancer through epithelial-mesenchymal transformation.
Wang X; Li Y; Fang Z; Li Y
Bioengineered; 2021 Dec; 12(2):12204-12214. PubMed ID: 34783304
[TBL] [Abstract][Full Text] [Related]
3. Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells.
Yu MM; Feng YH; Zheng L; Zhang J; Luo GH
World J Gastroenterol; 2019 Mar; 25(10):1210-1223. PubMed ID: 30886504
[TBL] [Abstract][Full Text] [Related]
4. NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer.
Qian J; Huang C; Zhu Z; He Y; Wang Y; Feng N; He S; Li X; Zhou L; Zhang C; Gong Y
Carcinogenesis; 2022 Jun; 43(5):457-468. PubMed ID: 35022660
[TBL] [Abstract][Full Text] [Related]
5. NFE2L3 as a Potential Functional Gene Regulating Immune Microenvironment in Human Kidney Cancer.
Zhang Q; Tang D; Zha A; He J; Li D; Chen Y; Cai W; Dai J; Luan S; Yin L; Zhang W; Dai Y
Biomed Res Int; 2022; 2022():9085186. PubMed ID: 36337840
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients.
Wang H; Zhan M; Yang R; Shi Y; Liu Q; Wang J
Cell Cycle; 2018; 17(17):2164-2174. PubMed ID: 30196752
[TBL] [Abstract][Full Text] [Related]
7. Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer.
Liu M; Wei H; Yang J; Chen X; Wang H; Zheng Y; Wang Y; Zhou Y
Front Genet; 2022; 13():916973. PubMed ID: 35846126
[TBL] [Abstract][Full Text] [Related]
8. NFE2L3 (NRF3): the Cinderella of the Cap'n'Collar transcription factors.
Chevillard G; Blank V
Cell Mol Life Sci; 2011 Oct; 68(20):3337-48. PubMed ID: 21687990
[TBL] [Abstract][Full Text] [Related]
9. NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression.
Waku T; Katayama H; Hiraoka M; Hatanaka A; Nakamura N; Tanaka Y; Tamura N; Watanabe A; Kobayashi A
Mol Cell Biol; 2020 Jun; 40(14):. PubMed ID: 32366381
[TBL] [Abstract][Full Text] [Related]
10. NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811.
Zhang L; Hu DL; Tang B; Cheng Y; Jiao C; Cheng L; Tan ZR; Zhou HH
Dis Markers; 2019; 2019():2829798. PubMed ID: 31191746
[TBL] [Abstract][Full Text] [Related]
11. NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53.
Ren Y; Yang J; Ding Z; Zheng M; Qiu L; Tang A; Huang D
Cancer Sci; 2023 Sep; 114(9):3523-3536. PubMed ID: 37350063
[TBL] [Abstract][Full Text] [Related]
12. Stringent Control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) Protein Degradation by FBW7 (F-box/WD Repeat-containing Protein 7) and Glycogen Synthase Kinase 3 (GSK3).
Kannan MB; Dodard-Friedman I; Blank V
J Biol Chem; 2015 Oct; 290(43):26292-302. PubMed ID: 26306035
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation-Mediated Upregulation of NFE2L3 Promotes Malignant Phenotypes of Clear Cell Renal Cell Carcinoma Cells.
Hou X; Liao Q; Wu Y; Wang L; Zhao J; Liao X
Mol Biotechnol; 2024 Feb; 66(2):198-207. PubMed ID: 37071304
[TBL] [Abstract][Full Text] [Related]
14. NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers.
Wang Z; Yang H; Luo B; Duan P; Lin P
Front Genet; 2022; 13():805256. PubMed ID: 35664314
[No Abstract] [Full Text] [Related]
15. NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor.
Bury M; Le Calvé B; Lessard F; Dal Maso T; Saliba J; Michiels C; Ferbeyre G; Blank V
Cell Rep; 2019 Nov; 29(6):1469-1481.e9. PubMed ID: 31693889
[TBL] [Abstract][Full Text] [Related]
16. Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment.
Saliba J; Coutaud B; Makhani K; Epstein Roth N; Jackson J; Park JY; Gagnon N; Costa P; Jeyakumar T; Bury M; Beauchemin N; Mann KK; Blank V
Oncogene; 2022 Mar; 41(11):1563-1575. PubMed ID: 35091681
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor NFE2L3 promotes the proliferation of esophageal squamous cell carcinoma cells and causes radiotherapy resistance by regulating IL-6.
Chen T; Xu B; Chen H; Sun Y; Song J; Sun X; Zhang X; Hua W
Comput Methods Programs Biomed; 2022 Nov; 226():107102. PubMed ID: 36108571
[TBL] [Abstract][Full Text] [Related]
18. Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer.
Palma M; Lopez L; García M; de Roja N; Ruiz T; García J; Rosell E; Vela C; Rueda P; Rodriguez MJ
BMC Clin Pathol; 2012 Feb; 12():2. PubMed ID: 22321245
[TBL] [Abstract][Full Text] [Related]
19. CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Hou W; Kong L; Hou Z; Ji H
BMC Med Genomics; 2022 Oct; 15(1):225. PubMed ID: 36316684
[TBL] [Abstract][Full Text] [Related]
20. Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer.
Mei D; Qi Y; Xia Y; Ma J; Hu H; Ai J; Chen L; Wu N; Liao D
World J Surg Oncol; 2021 Oct; 19(1):311. PubMed ID: 34686186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
